5 Weight-Loss Strategies That Don ’t Work—And What To Do Instead
Every year, losing weight ranks among the top New Year’s resolutions. And every year, we keep trying many of the same methods—and not surprisingly, keep getting the same disappointing results. The unfortunate truth is that most weight-loss strategies don’t work long term, and some can even make matters worse or cause other harms.
But that doesn’t mean trying to shed pounds is futile. Studies show that some approaches are, in fact, effective.
Here are five popular methods that often fail—and alternatives that are more likely to lead to long-term success.
1. Counting Calories
Tracking calories m...
Source: TIME: Health - January 20, 2023 Category: Consumer Health News Authors: Robert J. Davis Tags: Uncategorized freelance health Source Type: news
Flavored Cannabis Marketing Is Criticized for Targeting Kids Flavored Cannabis Marketing Is Criticized for Targeting Kids
Inside the store run by the nonprofit Housing Works, shelves brimmed with vape cartridges suggesting flavors of pineapple, grapefruit, and “cereal milk," written in rainbow bubble letter print.Associated Press (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 19, 2023 Category: Consumer Health News Tags: Pediatrics News Source Type: news
Now Caroline Ellison is selling grapefruits
(Source: Reuters: Health)
Source: Reuters: Health - January 11, 2023 Category: Consumer Health News Source Type: news
Iconic soccer legend Pel é dead at 82
Brazilian soccer legend Pelé has died at the age of 82, The Associated Press reported on Thursday. Born Edson Arantes do Nascimento, Pelé grew up in poverty in Barau, São Paulo, famously practicing his soccer skills with found items like a grapefruit before his meteoric rise in the sport he would…#nascimento #worldcup #barau #kelynascimento #brazilian #brazil #sãopaulo (Source: Reuters: Health)
Source: Reuters: Health - December 29, 2022 Category: Consumer Health News Source Type: news
The dieting 'red flags' experts are warning people to avoid
The British Dietetic Association (BDA) has published a list of 'red flags' to watch out for. Those highlighting the fat-burning effects of certain foods, like grapefruit and green tea, are warned against. (Source: the Mail online | Health)
Source: the Mail online | Health - December 27, 2022 Category: Consumer Health News Source Type: news
Real-World Study Shows Patients Treated with IMBRUVICA ® (ibrutinib) Were Less Likely to Initiate a Next-Line Treatment than Patients on Acalabrutinib in First-line Chronic Lymphocytic Leukemia
NEW ORLEANS, December 12, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results of a real-world study showing that patients with chronic lymphocytic leukemia (CLL) treated with first-line acalabrutinib monotherapy were 89 percent more likely to start a next-line treatment than those treated with IMBRUVICA® (ibrutinib).[1] These data suggest the potential that first-line treatment with IMBRUVICA® in routine practice may provide patients with the ability to use once-daily, all-oral IMBRUVICA® as a monotherapy treatment for a longer period without the need to start the next line of ...
Source: Johnson and Johnson - December 12, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA ® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia
NEW ORLEANS, December 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new four-year follow-up results from the Phase 3 GLOW study (Abstract #93), which showed investigational, fixed-duration treatment with IMBRUVICA® + venetoclax (I+V) reduced the risk of progression or death by 79 percent among older and/or unfit patients with previously untreated chronic lymphocytic leukemia (CLL) compared to patients treated with chemoimmunotherapy.[i] These results were highlighted in an oral presentation during the 2022 American Society of Hematology (ASH) Annual Meeting.1CLL is the most com...
Source: Johnson and Johnson - December 10, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Pharmacologist and Olympian David Bailey Dies at 77
He was best known for his discovery that grapefruit juice makes some medications less effective or potentially dangerous. (Source: The Scientist)
Source: The Scientist - October 7, 2022 Category: Science Tags: News & Opinion Source Type: news
Californian woman, 33, finds out she has 'grapefruit sized' cysts on ovaries
Farren Bay, now 33, had been struggling with periods that were so painful it felt like 'my insides were being ripped apart' for years. She was eventually diagnosed with endometriosis. (Source: the Mail online | Health)
Source: the Mail online | Health - September 22, 2022 Category: Consumer Health News Source Type: news
U.S. FDA Approves IMBRUVICA ® (ibrutinib) as First and Only BTKi Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease
August 24, 2022 (HORSHAM, PA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA® (ibrutinib) for the treatment of pediatric patients one year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy. This milestone marks the first pediatric indication for IMBRUVICA® and the introduction of a new oral suspension formulation for patients ages one to less than 12. IMBRUVICA® is now the first FDA-approved therapy for these younger patients who previously had no approv...
Source: Johnson and Johnson - August 24, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
New IMBRUVICA ® (ibrutinib) Data in Fixed-Duration Combination Regimen Presented at EHA 2022 Shows Deep, Durable Response at Three Years in Untreated Chronic Lymphocytic Leukemia
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new and updated results from the Phase 2 CAPTIVATE study evaluating IMBRUVICA® (ibrutinib) in combination with venetoclax (I+V) as a potential fixed-duration (FD) treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Updated data from the FD cohort with three years of follow-up shows that I+V continues to demonstrate deep and durable responses and clinically meaningful progression-free survival (PFS) and overall survival (OS) in the first-line tre...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Phase 3 SHINE Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen Significantly Reduced the Risk of Disease Progression or Death in Older Patients with Newly Diagnosed Mantle Cell Lymphoma
This study is one of the largest clinical trials ever conducted in first-line MCL and the first for a Bruton’s tyrosine kinase inhibitor (BTKi).[1] The data are being presented in an oral session and featured in a press briefing during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, and were published in The New England Journal of Medicine today. The data will also be presented as an oral presentation at the 2022 European Hematology Association (EHA) Annual Congress. MCL is a type of aggressive, rare non-Hodgkin lymphoma (NHL) that is incurable and difficult to treat.[2] It commonly affects people o...
Source: Johnson and Johnson - June 3, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen to Highlight Science, Innovation and Advances in Robust Oncology Portfolio and Pipeline Through More Than 60 Data Presentations at ASCO and EHA
RARITAN, N.J., May 31, 2022 — The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that new research and data from its robust oncology portfolio and pipeline of investigational therapies will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 3-7 in Chicago, and the European Hematology Association (EHA) 2022 Congress taking place in Vienna, Austria, June 9-12. More than 60 presentations from company-sponsored studies across the two congresses, including 14 oral presentations, will feature new data and updates for both approved and investigation...
Source: Johnson and Johnson - May 31, 2022 Category: Pharmaceuticals Source Type: news
What you eat could be stopping your medicines working
Citrus fruit, particularly grapefruit, is known to disrupt the absorption of at least 85 different medicines, from statins to antidepressants. (Source: the Mail online | Health)
Source: the Mail online | Health - May 30, 2022 Category: Consumer Health News Source Type: news
Startup Spotlight: Grapefruit Testing eyes up to $20M in funding to expand Covid-19 testing for schools and businesses
Founded by a Swarthmore College student and physicians from Einstein Healthcare Network and Virtua Health, the startup is looking to raise a $10 million to $20 million Series A round beginning in early 2022. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 8, 2021 Category: Pharmaceuticals Authors: Kennedy Rose Source Type: news
